.png)
6 days ago
27
editorial-team@simplywallst.com (Simply Wall St)
Thu, May 8, 2025, 6:18 AM 1 min read
In This Article:
-
Revenue: US$15.5m (up 7.5% from 1Q 2024).
-
Net loss: US$3.75m (loss widened by 12% from 1Q 2024).
-
US$0.20 nonaccomplishment per stock (further deteriorated from US$0.19 nonaccomplishment successful 1Q 2024).
Our escaped banal study includes 3 informing signs investors should beryllium alert of earlier investing successful Exagen. Read for escaped now.
All figures shown successful the illustration supra are for the trailing 12 period (TTM) period
Revenue exceeded expert estimates by 6.5%. Earnings per stock (EPS) besides surpassed expert estimates by 2.0%.
Looking ahead, gross is forecast to turn 13% p.a. connected mean during the adjacent 3 years, compared to a 17% maturation forecast for the Biotechs manufacture successful the US.
Performance of the American Biotechs industry.
The company's shares are up 9.6% from a week ago.
Before you instrumentality the adjacent measurement you should cognize astir the 3 informing signs for Exagen (1 can't beryllium ignored!) that we person uncovered.
Have feedback connected this article? Concerned astir the content? Get successful touch with america directly. Alternatively, email editorial-team (at) simplywallst.com.
This nonfiction by Simply Wall St is wide successful nature. We supply commentary based connected humanities information and expert forecasts lone utilizing an unbiased methodology and our articles are not intended to beryllium fiscal advice. It does not represent a proposal to bargain oregon merchantability immoderate stock, and does not instrumentality relationship of your objectives, oregon your fiscal situation. We purpose to bring you semipermanent focused investigation driven by cardinal data. Note that our investigation whitethorn not origin successful the latest price-sensitive institution announcements oregon qualitative material. Simply Wall St has nary presumption successful immoderate stocks mentioned.
English (US) ·